Immune System Disorders

Tokyo, Jan 31, 2012 - (JCN Newswire) - Hitachi Ltd and Hitachi High-Technologies Corporation today announced they had received the IEEE Milestone for Hitachi's pioneering development of the world's "First Practical Field Emission...

GS-7340 is a novel prodrug of tenofovir, the active agent in Viread, or tenofovir disoproxil fumarate. In previous studies, GS-7340 has demonstrated the ability to provide greater antiviral efficacy at a dose that...

CAMBRIDGE, Mass. -- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the European Medicines Agency (EMA) has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme([R])...

Program Provides Individuals the Opportunity to Learn from Leading Lupus Experts WASHINGTON -- The Lupus Foundation of America (LFA) has announced its 2012 topics and dates for its nationwide education series, Lupus: Learn...

Study also Demonstrated 100% Sustained Virologic Response 12-Weeks Post Treatment with Quadruple Therapy Phase II Investigational Data Published Today in the New England Journal of Medicine PRINCETON, N.J. -- Bristol-Myers Squibb Company (NYSE:...

Last Tuesday, Los Angeles City Council voted 11 to 1 to adopt a proposed ordinance that will tie adult film permits to condom use in the films; however, Council needed a super majority...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/f1260a/musculoskeletal_di) has announced the addition of the "Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014" report to their...

KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that nonclinical data on the immunologic mechanism of action of PV-10 will be presented at the...

ePharma Consumer ([R] ) Study Reveals New Trends around How Consumers Interact with Pharma, Including Customer Service Options, Patient Education, and Pharma Websites - Webinar January 25 at 2pm ET NEW YORK --...

THE WOODLANDS, Texas -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin([R]), a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/08f4d0/epidemiology_hepa) has announced the addition of the "Epidemiology: Hepatitis C in China - Epidemic yet to reach its peak" report to their offering. In 1999, an estimated 180 million...

NEW YORK & PETACH TIKVAH -- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced that the data from the...

Agreement Will Support New Agility Microplate Automation System CHANTILLY, Va. -- Dynex Technologies announced today it has finalized a supply agreement with ZEUS Scientific (Branchburg, NJ), allowing ZEUS to utilize the proprietary Dynex...

News this year are that the prize amount is doubled to totally SEK 8 million and that Video News Releases with experts from the prize committees, and newly recorded interviews with chosen Laureates...

KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that Craig Dees, Ph.D., CEO, will present at BOCEMb: Noble Financial Capital Markets' Eighth Annual...

CAMBRIDGE, Mass. -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its fourth quarter and full year 2011 financial results on Thursday, February 2, 2012 after the financial markets close. The company will host...

NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that dosing has initiated in a Phase 1 study of its hematopoietic growth factor, CDX-301, in healthy subjects. The study is being conducted...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/2dc9d4/empirical_model_bu) has announced the addition of John Wiley and Sons Ltd's new book "Empirical Model Building: Data, Models, and Reality, 2nd Edition" to their offering. This new edition features...

MIAMI BEACH, Fla. -- Although using angioplasty to treat multiple sclerosis (MS) is highly controversial, sufferers often insist it helps - in some cases dramatically, such as allowing them to walk without a...